Larimar Posts $31.1M Q3 Loss, Cash to Late Q2 2027 Ahead of BLA Acceptance
LRMR sits 51% above its 52-week low of $1.915 on elevated volume (1.9× avg).
Summary
Larimar reported a $31.1 million third-quarter loss and $128.7 million in cash with runway into late Q2 2027, while targeting BLA acceptance in early 2027 and a U.S. launch in Q3 2027 if approved.
Key Events · Earnings and Guidance · LRMR
-
Q3 Loss Narrows to $31.1M
Net loss was $31.1 million, or $0.29 per share, versus $47.7 million, or $0.61 per share, a year earlier; the nine-month loss was $93.5 million, or $0.90 per share.
-
Cash Runway Into Late Q2 2027
$128.7 million in cash, equivalents and marketable securities at September 30, 2026 ($76.99 million cash plus $51.67 million securities) funds operations into late Q2 2027.
-
Spend Mix Shifts Toward Launch
R&D fell to $25.9 million from $44.9 million on a $19.3 million cut in third-party manufacturing, while G&A rose to $6.5 million from $4.6 million on commercial preparation.
-
Milestone Calendar Laid Out
BLA acceptance is expected early 2027, with an open-label safety update in Q1 2027, U.S. approval mid-2027, priority review voucher monetization mid-2027, and launch targeted for Q3 2027 if approved.
Analysis · LRMR · Life Sciences
With the BLA completion and $128.7 million cash figure already out on November 9, the fresh information here is the quarterly numbers and the calendar. Larimar burned $31.1 million in the third quarter and ended September with $128.7 million, which management says funds operations into late Q2 2027 — before the mid-2027 U.S. approval decision it is targeting. A funding gap therefore opens if the FDA timeline slips, and the company has already expanded authorized common stock to 215 million from 115 million, room it will likely need. Spending is shifting: R&D fell $19.3 million on lower third-party manufacturing, while G&A rose on hiring and consultants for a launch that has not been approved.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LRMR was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.7M. The 52-week trading range was $1.92 to $6.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.